The Dow’s Best Health Care Stock: Merck & Co., Inc. (MRK)

Page 1 of 2

Investing in the health care sector isn’t easy. Where do you start out? From medical device companies to big pharma to small biotech firms bristling with boom-or-bust prospects, it’s tough for investors new to this sector to understand the intricacies unique to health care. Fortunately, there’s an easy place to look for blue-chip, tried-and-true stocks: the Dow Jones Industrial Average .

Four big-time health care stocks call the Dow home, but which one is the best pick for your money? In this five-part series, we’ll take an in-depth look into why each health care stock on the Dow is worth investing in — and in the final installment, we’ll select a winner. Yesterday we took a look at the present and future of big pharma giant Pfizer Inc. (NYSE:PFE); today, let’s check out one of its biggest rivals: Merck & Co., Inc. (NYSE:MRK).

Merck & Co., Inc. (NYSE:MRK)An income investor’s delight
Merck’s recent gains aren’t enough to raise eyebrows, but the stock’s still pleased investors lately. In the past 52 weeks, shares of the big pharma have gained more than 15%. However, things haven’t been so easy in the shorter term: The last three months have seen Merck lose 2.8% as the company struggles with patent expirations and their hit on revenue.

For income investors, however, Merck & Co., Inc. (NYSE:MRK)’s at the top of its game. The company offers a 4% dividend yield, tops among the health care stocks of the Dow and one of the highest-yielding stocks on the index overall. A payout ratio of 78% makes that high yield a pricey endeavor, however.

Growth investors will need to see more, however — particularly as Merck struggles to combat falling sales due to the patent cliff.

The present state of Merck’s drug portfolio
The loss of patent exclusivity on top-selling allergy and asthma blockbuster Singulair has undoubtedly hurt Merck’s pharmaceutical revenue. The drug’s still the company’s second-best-selling therapy, but sales plummeted 30% in 2012 due to generic competition. Merck & Co., Inc. (NYSE:MRK)’s going to have to kick its other medications into high gear in order to make up the more than $1.6 billion in lost sales.

Fortunately, some of Merck’s others therapies are picking up the slack. HPV vaccine Gardasil has come on strong in recent years, posting a nearly 35% gain in 2012 after hitting blockbuster status a year earlier. With Gardasil’s patent exclusivity lasting way down the road until 2028 — and an increasing public awareness about the dangers of HPV recently — count on this vaccine to remain a staple of Merck’s pharmaceutical revenue for years to come.

Merck’s already-on-the-market drug of the future, however, is the Januvia and Janumet family of diabetes therapies. These drugs are already a foundation of Merck’s success, with a combined $5.7 billion in 2012 sales; however, there’s room for even more growth. Don’t expect the diabetes market to slow down any time soon with obesity rates rising across the world. The drug family saw much of its 23% growth last year in the U.S. and Japan, and if Merck can expand that success elsewhere — particularly in emerging markets, no stranger to climbing obesity rates — Januvia and Janumet could make investors forget all about Singulair.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

The 50 Best Personal Finance Blogs

Most Expensive Apartments in New York City

Bloodiest UFC Fights Ever Fought

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!